Lower cost and shorter delivery time compared to conventional protein expression! For vaccine development.
The "Silkworm-based Useful Protein Production Platform" can be utilized for vaccine development. For "Norovirus," we have confirmed an increase in antibody levels through animal testing and are exploring partnerships with pharmaceutical companies. For "Porcine Virus," we have a production capacity of 500 shots per silkworm, and we will begin clinical trials with an animal pharmaceutical manufacturer this fall. Additionally, we will supply investigational drugs through GMP manufacturing starting next fall. [Features] ■ Novel Coronavirus Spike Protein ■ Norovirus Virus-like Particles ■ Porcine Virus Virus-like Particles *For more details, please refer to the PDF document or feel free to contact us.
Inquire About This Product
basic information
For more details, please refer to the PDF document or feel free to contact us.
Price range
Delivery Time
Applications/Examples of results
【Usage】 ■Vaccine *For more details, please refer to the PDF document or feel free to contact us.
catalog（1）
Download All Catalogs![[Essential for Pharmaceutical Manufacturers] Useful Protein Production Platform](https://image.mono.ipros.com/public/catalog/image/01/033/549974/IPROS54606633501085751261.jpeg?w=120&h=170)
Company information
Our company is a university-based venture founded on the technology of Kyushu University. We have adopted the technology for recombinant protein expression using silkworms, which has been developed through research by Professor Kusakabe from the Graduate School of Agricultural Sciences (insect molecular genetics). Additionally, by utilizing the protein structure analysis, analysis, and reconstruction technology researched by Professor Kamiya from the Graduate School of Engineering (biotechnology, enzyme engineering, and biomolecular engineering), we aim to produce not only difficult-to-express proteins but also unique proteins.